We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ
Johnson & Johnson (JNJ - Free Report) and Albertsons Companies' (ACI - Free Report) stock have provided a pleasant hedge against market volatility, with the S&P 500 and Nasdaq remaining near correction territory. Meanwhile, ACI and JNJ shares are up a respectable 6% year to date, respectively.
Furthermore, the pharmaceutical giant and grocery retailer were able to exceed their quarterly expectations on Wednesday, and investors may be wondering if it’s time to add positions in these defensive-performing stocks.
Image Source: Zacks Investment Research
Johnson & Johnson’s Q1 Results
Attributed to DARZALEX, a drug treatment for myeloma blood cancer, Johnson & Johnson’s Q1 sales rose 2% to $21.89 billion and eclipsed estimates of $21.61 billion. This marked Johnson & Johnson’s third straight quarter with sales of more than $3 billion, as DARZALEX had another quarter of 20% growth.
On the bottom line, Q1 earnings increased 2% to $2.77 per share, comfortably exceeding EPS expectations of $2.57 by 7.78%. Notably, Johnson & Johnson has continued a prolonged streak of passing the Zacks EPS consensus with an average earnings surprise of 5.71% in its last four quarterly reports.
Image Source: Zacks Investment Research
Albertsons’ Q4 Results
Reporting results for its fiscal fourth quarter, Albertsons' Q4 sales were up 2% to $18.79 billion, surpassing estimates of $18.62 billion. Digital platforms led to what CEO Vivek Sankaran cited as getting the company’s mojo back since the termination of the Kroger (KR - Free Report) merger, with E-commerce sales spiking 24%. It’s noteworthy that Sankaran will be retiring at the end of the month and will be replaced by VP & COO Susan Morris.
Albertsons' Q4 EPS of $0.46 beat expectations of $0.40 despite falling from $0.54 a share in the comparative quarter. Albertsons has reached or exceeded the Zacks EPS Consensus in each of the last four quarters with an average earnings surprise of 7.21%.
Guidance & Outlook
Raising its top-line guidance, Johnson & Johnson now expects full-year sales at $91 billion-$91.8 billion, which came in above the current Zacks Consensus of $89.99 billion. Based on Zacks estimates, Johnson & Johnson’s sales are projected to rise another 4% in FY26 to $93.47 billion.
However, Johnson & Johnson did lower its FY25 EPS guidance to reflect the implications of tariff costs from a a range of $10.75-$10.95 to $10.50-$10.70. Still, this EPS outlook fell in line with estimates of $10.51 or 5% growth. Plus, Zacks' projections call for Johnson & Johnson's annual earnings to increase 4% in FY26 to $10.99.
Image Source: Zacks Investment Research
As for Albertsons, the grocer provided EPS guidance for its current FY26 in the range of $2.03-$2.16, which came in below expectations of $2.33 and would be a shaprer decline from earnings of $2.34 per share in FY25. That said, FY27 EPS is projected to rebound and rise 5% to $2.44 per share.
Albertsons' sales are expected to increase 3% in FY26 and are forecasted to expand another 1% in FY27 to $83.25 billion.
Image Source: Zacks Investment Research
Bottom Line
For now, Johnson & Johnson and Albertsons stock both land a Zacks Rank #3 (Hold). To that point, the defensive safety they can provide may continue thanks to the essentiality of their businesses, but there could certainly be better buying opportunities considering their somewhat underwhelming guidance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ
Johnson & Johnson (JNJ - Free Report) and Albertsons Companies' (ACI - Free Report) stock have provided a pleasant hedge against market volatility, with the S&P 500 and Nasdaq remaining near correction territory. Meanwhile, ACI and JNJ shares are up a respectable 6% year to date, respectively.
Furthermore, the pharmaceutical giant and grocery retailer were able to exceed their quarterly expectations on Wednesday, and investors may be wondering if it’s time to add positions in these defensive-performing stocks.
Image Source: Zacks Investment Research
Johnson & Johnson’s Q1 Results
Attributed to DARZALEX, a drug treatment for myeloma blood cancer, Johnson & Johnson’s Q1 sales rose 2% to $21.89 billion and eclipsed estimates of $21.61 billion. This marked Johnson & Johnson’s third straight quarter with sales of more than $3 billion, as DARZALEX had another quarter of 20% growth.
On the bottom line, Q1 earnings increased 2% to $2.77 per share, comfortably exceeding EPS expectations of $2.57 by 7.78%. Notably, Johnson & Johnson has continued a prolonged streak of passing the Zacks EPS consensus with an average earnings surprise of 5.71% in its last four quarterly reports.
Image Source: Zacks Investment Research
Albertsons’ Q4 Results
Reporting results for its fiscal fourth quarter, Albertsons' Q4 sales were up 2% to $18.79 billion, surpassing estimates of $18.62 billion. Digital platforms led to what CEO Vivek Sankaran cited as getting the company’s mojo back since the termination of the Kroger (KR - Free Report) merger, with E-commerce sales spiking 24%. It’s noteworthy that Sankaran will be retiring at the end of the month and will be replaced by VP & COO Susan Morris.
Albertsons' Q4 EPS of $0.46 beat expectations of $0.40 despite falling from $0.54 a share in the comparative quarter. Albertsons has reached or exceeded the Zacks EPS Consensus in each of the last four quarters with an average earnings surprise of 7.21%.
Guidance & Outlook
Raising its top-line guidance, Johnson & Johnson now expects full-year sales at $91 billion-$91.8 billion, which came in above the current Zacks Consensus of $89.99 billion. Based on Zacks estimates, Johnson & Johnson’s sales are projected to rise another 4% in FY26 to $93.47 billion.
However, Johnson & Johnson did lower its FY25 EPS guidance to reflect the implications of tariff costs from a a range of $10.75-$10.95 to $10.50-$10.70. Still, this EPS outlook fell in line with estimates of $10.51 or 5% growth. Plus, Zacks' projections call for Johnson & Johnson's annual earnings to increase 4% in FY26 to $10.99.
Image Source: Zacks Investment Research
As for Albertsons, the grocer provided EPS guidance for its current FY26 in the range of $2.03-$2.16, which came in below expectations of $2.33 and would be a shaprer decline from earnings of $2.34 per share in FY25. That said, FY27 EPS is projected to rebound and rise 5% to $2.44 per share.
Albertsons' sales are expected to increase 3% in FY26 and are forecasted to expand another 1% in FY27 to $83.25 billion.
Image Source: Zacks Investment Research
Bottom Line
For now, Johnson & Johnson and Albertsons stock both land a Zacks Rank #3 (Hold). To that point, the defensive safety they can provide may continue thanks to the essentiality of their businesses, but there could certainly be better buying opportunities considering their somewhat underwhelming guidance.